Drugs in Development: From Pipeline to Market 2011PharmaLive Special Reports
July 1, 2011
102 Pages - SKU: ENPP6526280
Additional InformationAlso included in this report:
- Top R&D spenders of 2010, and the number of drugs in development by therapeutic category
- Comprehensive listing of companies and the therapeutic categories in which they are developing
- Comparison of 2010-2011 top ten therapeutic categories against 2009-2010
- Alphabetical listing of drugs in development, including their therapeutic area
More United States Clinical Trial reports
TreatmentTrends®: Advanced/Metastatic Breast Cancer (US) 2012 by Decision Resources
This report series examines the current trends in the management of Advanced / Metastatic Breast Cancer from the perspective of medical oncologists. TreatmentTrends® are syndicated ...
ChartTrends®: Lupus (US) 2012 by Decision Resources
This report is an annual publication that provides comprehensive insight into the management of systemic lupus erythematosus (SLE) patients being treated with immunosuppressants, corticosteroids, anti-malarials, ...
ChartTrends®: Bone and Mineral Metabolism in CKD-ND (US) 2012 by Decision Resources
ChartTrends®: Bone and Mineral Metabolism in CKD is a syndicated report that captures patient level data from 1000+ unique late stage (Stage 3 / Stage ...
Early Toxicology: Markets and Approaches by Kalorama InformationSee all reports like this >>
Early toxicology testing is emerging as one of the mostsignificant areas of drug discovery. Toxicity is no longer something that can be left to the ...
More United States reports
The 2013-2018 Outlook for Relish in the United States by Icon Group International, Inc.
This econometric study covers the latent demand outlook for relish across the states and cities of the United States. Latent demand (in millions of U.S. ...
The 2013-2018 Outlook for Indian Breads in the United States by Icon Group International, Inc.
This econometric study covers the latent demand outlook for Indian breads across the states and cities of the United States. Latent demand (in millions of ...
D&B Country RiskLine Report: The United States of America by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
D&B Country Report: The United States of America by Dun & Bradstreet Inc.See all reports like this >>
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
We can help you find what you need. Call us or write us:
Need help in your search?
Clinical Trial Reports
- Perspective: StudyOptimizer — Empowering Clinical Trial Enrollment Collaboration at Big Pharma
- Radiculopathy Global Clinical Trials Review, H1, 2013
- Dystonia Global Clinical Trials Review, H1, 2013
- Dyskinesia Global Clinical Trials Review, H1, 2013
- Diverticulitis Global Clinical Trials Review, H1, 2013